Copyright
©The Author(s) 2016.
World J Gastroenterol. Jul 14, 2016; 22(26): 5950-5957
Published online Jul 14, 2016. doi: 10.3748/wjg.v22.i26.5950
Published online Jul 14, 2016. doi: 10.3748/wjg.v22.i26.5950
Table 1 Characteristics of randomized trials evaluating selective intestinal decontamination in liver transplant
Ref. | Type of study | SID regimen | Treatment perioperative (48 h) | Patients (n) | Patients with infection, n (%) | Period of observation posttransplantation (d) | ||
SID | Control | SID | Control | |||||
Bion et al[50], 1994 | Randomized trial not placebo controlled | Tobramycin, amphotericin and polymyxin B for 5-15 d posttransplantation | Cefotaxime and ampicillin | 21 | 31 | 3 (14.3) | 12 (38.7) | 15 d or until hospital discharge |
Arnow et al[51], 1996 | Randomized trial not placebo controlled | Gentamicin, polymyxin and nystatin orally for 21 d posttransplantation | Cefotaxime and ampicillin | 36 | 33 | 14 (38.9) | 14 (42.4) | 28 |
Hellinger et al[53], 2002 | Randomized placebo-controlled trial | Gentamicin, polymyxin E and nystatin 4 x/d for 21 d posttransplantation | Ceftizoxime | 37 | 43 | 12 (32.4) | 12 (28.9) | 60 |
Zwaveling et al[28], 2002 | Randomized placebo-controlled trial | Norfloxacin, colitin,tobramycin and amphotericin B | Cefotaxime and tobramycin | 29 | 29 | 22 (75.9) | 25 (86.2) | 30 |
- Citation: Resino E, San-Juan R, Aguado JM. Selective intestinal decontamination for the prevention of early bacterial infections after liver transplantation. World J Gastroenterol 2016; 22(26): 5950-5957
- URL: https://www.wjgnet.com/1007-9327/full/v22/i26/5950.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i26.5950